Johnson & Johnson (JNJ) Holdings Held by Solaris Asset Management LLC
Solaris Asset Management LLC continued to hold its stake in Johnson & Johnson (NYSE:JNJ) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,609 shares of the company’s stock at the end of the 2nd quarter. Solaris Asset Management LLC’s holdings in Johnson & Johnson were worth $213,000 at the end of the most recent reporting period.
A number of other large investors have also recently made changes to their positions in the stock. OLD Point Trust & Financial Services N A lifted its position in shares of Johnson & Johnson by 2.2% during the 2nd quarter. OLD Point Trust & Financial Services N A now owns 61,326 shares of the company’s stock valued at $8,113,000 after acquiring an additional 1,321 shares during the period. Lynch & Associates IN lifted its position in shares of Johnson & Johnson by 0.9% during the 2nd quarter. Lynch & Associates IN now owns 93,710 shares of the company’s stock valued at $12,397,000 after acquiring an additional 841 shares during the period. Welch & Forbes LLC lifted its position in shares of Johnson & Johnson by 0.9% during the 2nd quarter. Welch & Forbes LLC now owns 718,331 shares of the company’s stock valued at $95,028,000 after acquiring an additional 6,730 shares during the period. Oakbrook Investments LLC lifted its position in shares of Johnson & Johnson by 7.4% during the 2nd quarter. Oakbrook Investments LLC now owns 136,124 shares of the company’s stock valued at $18,008,000 after acquiring an additional 9,375 shares during the period. Finally, Janney Montgomery Scott LLC lifted its position in shares of Johnson & Johnson by 0.5% during the 2nd quarter. Janney Montgomery Scott LLC now owns 771,868 shares of the company’s stock valued at $102,110,000 after acquiring an additional 3,533 shares during the period. Hedge funds and other institutional investors own 65.61% of the company’s stock.
JNJ has been the subject of a number of research reports. Goldman Sachs Group, Inc. (The) downgraded shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and lifted their price target for the company from $125.00 to $130.00 in a research report on Wednesday, September 20th. BMO Capital Markets reiterated a “buy” rating and set a $145.00 price target on shares of Johnson & Johnson in a research report on Friday, September 1st. Vetr upgraded Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 price objective for the company in a research report on Monday, October 30th. Credit Suisse Group set a $154.00 price objective on Johnson & Johnson and gave the stock an “outperform” rating in a research report on Thursday, October 19th. Finally, UBS AG restated an “underweight” rating on shares of Johnson & Johnson in a research report on Thursday, August 24th. Four analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $143.70.
Shares of Johnson & Johnson (NYSE:JNJ) opened at $138.00 on Monday. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $144.35. The stock has a market cap of $370,739.75, a price-to-earnings ratio of 19.33, a PEG ratio of 2.80 and a beta of 0.82. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The company had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. During the same period in the previous year, the company earned $1.68 EPS. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. sell-side analysts predict that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, November 27th. This represents a $3.36 annualized dividend and a dividend yield of 2.43%. Johnson & Johnson’s dividend payout ratio is presently 58.33%.
COPYRIGHT VIOLATION NOTICE: “Johnson & Johnson (JNJ) Holdings Held by Solaris Asset Management LLC” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.thecerbatgem.com/2017/11/20/johnson-johnson-jnj-holdings-held-by-solaris-asset-management-llc.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.